Cargando…
Old Drugs with New Tricks: Efficacy of Fluoroquinolones to Suppress Replication of Flaviviruses
Repurposing FDA-approved compounds could provide the fastest route to alleviate the burden of disease caused by flaviviruses. In this study, three fluoroquinolones, enoxacin, difloxacin and ciprofloxacin, curtailed replication of flaviviruses Zika (ZIKV), dengue (DENV), Langat (LGTV) and Modoc (MODV...
Autores principales: | Scroggs, Stacey L. P., Andrade, Christy C., Chinnasamy, Ramesh, Azar, Sasha R., Schirtzinger, Erin E., Garcia, Erin I., Arterburn, Jeffrey B., Hanley, Kathryn A., Rossi, Shannan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551155/ https://www.ncbi.nlm.nih.gov/pubmed/32933138 http://dx.doi.org/10.3390/v12091022 |
Ejemplares similares
-
Evolution of resistance to fluoroquinolones by dengue virus serotype 4 provides insight into mechanism of action and consequences for viral fitness
por: Scroggs, Stacey L.P., et al.
Publicado: (2021) -
Support for the Transmission-Clearance Trade-Off Hypothesis from a Study of Zika Virus Delivered by Mosquito Bite to Mice
por: Hanley, Kathryn A., et al.
Publicado: (2019) -
Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus
por: Hanley, Kathryn A, et al.
Publicado: (2008) -
Inhibitors compounds of the flavivirus replication process
por: García, Leidy L., et al.
Publicado: (2017) -
Aedes aegypti Shows Increased Susceptibility to Zika Virus via Both In Vitro and In Vivo Models of Type II Diabetes
por: Azar, Sasha R., et al.
Publicado: (2022)